Alzheimer’s Disease | Unmet Need | Mild to Moderate | US/EU | 2016
The need for improved AD therapeutics is considerable; current treatment options are limited, and none can cease or even delay the inexorable cognitive and functional decline caused by the disease. Mild to moderate AD is a key area of focus and commercial opportunity for the pharmaceutical industry: early-stage AD patients are the prime targets for disease-modifying interventions—the Holy Grail in AD drug development—and are also candidates for improved symptomatic options, which hinge on maximizing the function of existing neurons. New entrants that can safely deliver therapeutic gains over current mainstays are sought after by physicians, patients and their families, and healthcare systems that face a rapidly expanding AD population.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
